[1]谭梅娟,李 靖.首发精神分裂症患者抗精神病药物治疗对血脂代谢水平的影响研究[J].现代检验医学杂志,2019,34(02):91-93.[doi:10.3969/j.issn.1671-7414.2019.02.024]
　TAN Mei-juan,LI Jing.Effect of Antipsychotics on Blood Lipid Metabolismin Patients with First-Episode Schizophrenia[J].Journal of Modern Laboratory Medicine,2019,34(02):91-93.[doi:10.3969/j.issn.1671-7414.2019.02.024]
点击复制

首发精神分裂症患者抗精神病药物治疗对血脂代谢水平的影响研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年02期
页码:
91-93
栏目:
论著
出版日期:
2019-05-11

文章信息/Info

Title:
Effect of Antipsychotics on Blood Lipid Metabolismin Patients with First-Episode Schizophrenia
文章编号:
1671-7414(2019)02-091-04
作者:
谭梅娟1; 李 靖2
(1.湖南省脑科医院,长沙 410007; 2.长沙市第一医院,长沙 410005)摘 要:目的 探讨抗精神病药对首发精神分裂症住院患者血脂代谢的影响。方法 对2014年6月1日～2015年5月31日期间符合美国《精神障碍诊断统计手册》第四版(DSM-Ⅳ)精神分裂症的诊断,并根据DSM-IV-TR轴Ⅰ障碍用临床定式检查(SCID-Ⅰ/P)进行评定、复核确诊的137例首发精神分裂症住院患者进行观察,根据服用的不同抗精神病药物(FGA组、SGA组和联合用药)进行分组,并随访1年后测定其总胆固醇、高密度脂蛋白胆
Author(s):
TAN Mei-juan1; LI Jing2
(1.Brain Hospital of Hunan Province,Changsha 410007,China; 2.the First Hospital of Changsha,Changsha 410005,China)
关键词:
抗精神病药;  血脂代谢;  首发精神分裂症
分类号:
R749.3; R446.112
DOI:
10.3969/j.issn.1671-7414.2019.02.024
文献标志码:
A
摘要:
目的 探讨抗精神病药对首发精神分裂症住院患者血脂代谢的影响。方法 对2014年6月1日～2015年5月31日期间符合美国《精神障碍诊断统计手册》第四版(DSM-Ⅳ)精神分裂症的诊断,并根据DSM-IV-TR轴Ⅰ障碍用临床定式检查(SCID-Ⅰ/P)进行评定、复核确诊的137例首发精神分裂症住院患者进行观察,根据服用的不同抗精神病药物(FGA组、SGA组和联合用药)进行分组,并随访1年后测定其总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和三酰甘油等血脂情况。结果 随访1年后,首发精神分裂症住院患者服用SGA组和联合用药(FGA+SGA)组总胆固醇水平分别为4.69±0.64 mmol/L和4.53±0.78 mmol/L,均高于FGA组4.32±0.73 mmol/L,且差异有统计学意义(F=3.435,P<0.05); SGA组和联合用药(FGA+SGA)组低密度脂蛋白胆固醇水平分别为2.51±0.39 mmol/L和2.42±0.46 mmol/L,亦高于FGA组2.35±0.61 mmol/L,且差异有统计学意义(F=3.231,P<0.05)。结论 首发精神分裂症住院患者单用第二代抗精神病药物治疗及联合用药治疗均比单用第一代抗精神病药物更容易引发脂代谢异常。
Abstract:
Objective To explore the effect of antipsychotics on the blood lipid metabolism in the first-episode schizophrenia.Methods The patients with first-episode schizophrenia from June 1,2014 to May 31,2015 were met with the diagnosis of schizophrenia in the fourth edition(DSM-Ⅳ)of American Handbook of Diagnostic Statistics for Mental Disorder,and assessed them according to SCID-Ⅰ/ P.The patients were divided into groups according to different antipsychotic drugs and followed up for 1 year to collect the blood lipids including total cholesterol(TC),high density lipoprotein(HDL-C),low density lipoprotein(LDL-C)and triglyceride(TG).Results The total cholesterol levels in SGA group and FGA+SGA group were 4.69±0.64 mmol/L and 4.53±0.78 mmol/L,respectively,which were higher than those in FGA group 4.32±0.73 mmol/L.The difference was statistically significant(F=3.435,P<0.05).The levels of LDL in SGA group and(FGA+SGA)group were 2.51±0.39 mmol/L and 2.42±0.46 mmol/L,respectively,which were also higher than those in FGA group 2.35±0.61 mmol/L,and the difference was statistically significant(F=3.231,P<0.05).ConclusionThe second generation antipsychotics alone and combination therapyare more likely to cause lipid metabolism abnormality than the first generationantipsychotics alone in first-episode schizophrenia.

参考文献/References:

[1] CHARLSON F J,FERRARI A J,SANTOMAURO D F,et al.Global epidemiology and burden of schizophrenia:findings from the global burden of disease study 2016[J].Schizophr Bull,2018,44(6):1195-1203.
[2] TAKEUCHI Y,KAJIYAMA K,ISHIGURO C,et al.Atypical antipsychotics and the risk of hyperlipidemia:a sequence symmetry analysis[J].Drug Saf,2015,38(7):641-650.
[3] ROJO L E,GASPAR P A,SILVA H,et al.Metabolic syndrome and obesity among users of second generation antipsychotics:A global challenge for modern psychopharmacology[J].Pharmacol Res,2015,101:74-85.
[4] 张云淑,司天梅,栗克清.中国十省市第一代及第二代抗精神病药使用现况调查[J].中国心理卫生杂志,2012,26(10):736-740. ZHANG Yunshu,SI Tianmei,LI Keqing.A survey of antipsychotic usagein treatment of schizophrenia in China 2006[J].Chinese Mental Health Journal,2012,26(10):736-740.
[5] STROUP T S,GERHARD T,CRYSTAL S,et al.Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia[J].Am J Psychiatry,2016,173(2):166-173.
[6] SADIBA(ˇoverS)IC' B,MACIC'-D(ˇoverZ)ANKOVIC' A,(ˇoverS)ABIC' A,et al.The incidence of dyslipidemia(hypertriglyceridemia and hypercholesterolemia)in patients treated with the new generation of antipsychotic drugs compared to conventional therapy[J].Med Glas(Zenica),2014,11(2):350-355.
[7] ENGER C,JONES M E,KRYZHANOVSKAYA L,et al.Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia[J].Int J Adolesc Med Health,2013,25(1):3-11.
[8] TSE L,PROCYSHYN R M,FREDRIKSON D H,et al.Pharmacological treatment ofantipsychotic-induced dyslipidemia and hypertension[J].Int Clin Psychopharmacol,2014,29(3):125-137.
[9] HORSDAL H T,BENROS M E,K(¨overO)HLER-FORSBERG O,et al.Metabolic profile at first-time schizophrenia diagnosis:a population-based cross-sectional study[J].Neuropsychiatr Dis Treat,2017,13:621-630.
[10] MUNDET-TUDUR X,IGLESIAS-RODAL M,OLMOS-DOMíNGUEZ C,et al.Cardiovascular risk factors in chronic treatment with antipsychotic agents usedin primary care[J].Rev Neurol,2013,57(11):495-503.
[11] WANG Wei,BAI Mengru,JIANG Ting,et al.Clozapine-induced reduction ofL-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice[J].Toxicol Appl Pharmacol,2019,363:47-56.
[12] RONSLEY R,NGUYEN D,DAVIDSON J,et al.Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children:a prospective cohort study[J].Canadian Journal Psychiatry,2015,60(10):441-450.
[13] OLOSE E O,EDET J,IGWE M N,et al.Dyslipidaemia and medical outcome(health related quality of life)in patients with schizophrenia taking antipsychotics in Enugu,Nigeria[J].Psychiatry J,2017,2017:9410575.
[14] KAWABE K,OCHI S,YOSHINO Y,et al.Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics[J].Ther Adv Psychopharmacol,2015,5(5):271-277.
[15] VERDOUX H,GAUDRON Y,AULELEY G R,et al.Metabolic testing rates afterinitiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers[J].Encephale,2013,39(Suppl 1):S22-S28.

备注/Memo

备注/Memo:
基金项目:湖南省自然科学基金项目(2015JJ6084); 湖南省卫生计生委科研基金课题(B2015-105)。 作者简介:谭梅娟(1978-),女,硕士,副主任医师,主要从事临床流行病学研究,E-mail:tanmeijuan@tom.com。 收稿日期:2019-02-05 修回日期:2019-02-23 页码：93+99
更新日期/Last Update: 2019-04-30